4142:TPE
Adimmune Corp
NT$16.60
arrow_downward
-1.19%(-0.20) 1 日
11月11日, 13:30:09 GMT+8 · TWD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto4142 の上位の分析情報を生成しています...
始値
NT$16.85
高値
NT$16.90
安値
NT$16.50
時価総額
71.30億
平均出来高
112.30万
取引量
87.62万
52 週高値
NT$22.50
52 週安値
NT$15.65
EPS
-NT$0.34
発行済株式数
2.35億
従業員数
564
始値
NT$16.85
高値
NT$16.90
安値
NT$16.50
時価総額
71.30億
平均出来高
112.30万
取引量
87.62万
52 週高値
NT$22.50
52 週安値
NT$15.65
EPS
-NT$0.34
発行済株式数
2.35億
従業員数
564
ニュース記事
情報源: ウェブソース、ニュース パートナー
FOREX.com
·
2 時間前
S&P 500 Forecast: SPX rebounds amid revived AI enthusiasm
FXStreet
·
4 時間前
AI spending fears threaten S&P 500 recovery
TradingView
·
1 時間前
S&P 500, Nasdaq rise as CoreWeave results ease AI spending worries
Traders Union
·
2 時間前
S&P 500 holds at key technical levels, Ryan Detrick notes
プロフィール
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp について